Biomarker Operations and Biospecimen Management Summit - Boston, MA

Standardize and Scale Biomarker Operations Across Increasingly Complex Trials to Prevent Critical Delays and Keep Studies On Track

For the very first time, the biomarker and biospecimen management community will have a forum solely dedicated to this rapidly expanding and ever-increasingly critical function.

As trials expand globally and become more sample-intensive, protecting sample integrity and turning specimen data into trustworthy decisions has never mattered more. The inaugural Biomarker Operations and Biospecimen Management Summit provides a long-overdue home to share experiences and define the standards this field now demands.

Following the complete sample lifecycle, from kit design and site collection, through to tracking, storage, biobanking, lab coordination and data harmonization, walk away with the real-time insights needed to implement robust, scalable biomarker and biospecimen operations.

Join 120+ fellow senior leaders from biopharma, labs, CROs, and biobanks, in the united mission of ensuring every sample is treated with the precision, rigor and care it requires.

URLs:
Website: https://go.evvnt.com/3764960-0?pid=2874
Brochure: https://go.evvnt.com/3764960-3?pid=2874

Category: Conferences | Science, Health and Medicine

Prices:
Drug Developer - Conference Only *FREE: USD 0.50,
Service Provider - Conference Only: USD 3899.00,
Drug Developer - Conference Only - Additional Colleagues: USD 1099.00

Speakers: Benoit Destenaves, Head, Oncology Translational Medicine Operations and Experimental Oncology, AstraZeneca, Sachi Parikh, Director, Biomarker Operations, BioNTech, Anna Kosenko, Associate Director, Biomarker Operations, BioNTech, Maria Gujral, Senior Director and Head of Biospecimen Management, Bristol Myers Squibb, Karina Bienfait, Executive Director and Head, Consent, Biospecimen and Imaging Management, Bristol Myers Squibb, Cristin Palumbo Freeman, Senior Director and Head, Informed Consent Management, Bristol Myers Squibb, Narasimha Rao Marella, Associate Vice President, Clinical Biomarker and Diagnostics Operations, Eli Lilly and Co., Jonathan Hicks, Director and Head, Human Biospecimen Delivery, GlaxoSmithKline, Medha Kamat, Director, Oncology Biomarker and Diagnostic Operations, Johnson and Johnson, Bethany Brunton, Associate Director, Biomarker and Diagnostic Operations, Johnson and Johnson, Nancy DeFusco, Senior Director, Specimen Lifecycle Management, Merck and Co, Jonathan Saunders, Senior Director, Biomarker Operations, Moderna, Deborah Shepard, Director - Biomarker Clinical Data Acquisition and Program Lead, Pfizer, Eduardo Rodriguez Almaraz, Senior Manager, Precision Medicine and Clinical Operations Lead, Regeneron Pharmaceuticals, Michel Tarabocchi,a Director, Precision Medicine Operations, Regeneron Pharmaceuticals, Kristina McGuire, Executive Director, Biomarker Operations and Companion Diagnostics, Regeneron Pharmaceuticals, Nicole Couture, Director, Biosample Operations, Arcus Biosciences, Alyssa Masciarelli, Manager, Biomarker Operations, Bicycle Therapeutics plc, Jessica Dwyer, Associate Director, Translational Medicine, Candel Therapeutics, Michelle Hoarty, Senior Director, Translational Biomarkers, Dyne Therapeutics, Anupama Ravi, Director, Clinical Operations, Revolution Medicines, Jaime Fensterl, Senior Director, Translational Operations and Regulatory Integration, Sarepta Therapeutics, Brenda Yanak, Co-Founder, Biospecimen Industry Collaboration, Amy Ripston, Co-Founder and President, Biospecimen Management Consortium, Mine Cicek, Director, Biorepositories Program, Mayo Clinic, Lokesh Agrawal, Chief (Acting) Biorepositories and Biospecimen Research Branch (BBRB) Cancer Diagnosis Program, National Institute of Health Science